Glanzmann's thrombasthenia (GT) is a rare bleeding disorder characterized by spontaneous mucocutaneous bleeding. The disorder is caused by quantitative or qualitative defects in integrin αIIbβ3 (encoded by ITGA2B and ITGB3) on the platelet and is more common in consanguineous populations. However, the prevalence rate and clinical characteristics of GT in non-consanguineous populations have been unclear. We analyzed 97 patients from 93 families with GT in the Han population in China. This analysis showed lower consanguinity (18.3%) in
| INTRODUCTION
Glanzmann's thrombasthenia (GT) is a rare autosomal recessive genetic bleeding syndrome characterized by defects in platelet aggregometry. Its incidence is approximately one in one million. 1 Integrin αIIbβ3, composed of αIIb and β3 subunits, plays a vital role in platelet aggregation by serving as a specific receptor for fibrinogen. The gene ITGA2B, located on chromosome 17q21.31, codes for the platelet GP αIIβ, while the gene ITGB3, coding for the glycoprotein subunit β3, is located on chromosome 17q21.32. Pathogenic variants in either subunit can lead to a quantitative or qualitative defect in αIIbβ3 to cause GT. While we have made some progress in understanding GT, many questions remain unanswered.
The clinical phenotype of patients with GT is variable. 2, 3 Some suffer from severe bleeding, while others have only mild bleeding. It could present as petechiae, purpura, mild bruising, recurrent epistaxis, gingival bleeding and menorrhagia, gastrointestinal bleeding, intracranial hemorrhage or hematuria. Spontaneous remission with age can also occur in most patients; however, some patients' conditions worsen after adulthood. 2, 4 Some studies found bleeding severity in GT was not only influenced by the extent of αIIbβ3 deficiency but also the abundance and functioning of other platelet receptors involved in aggregation and adhesion. [5] [6] [7] However, the clinical phenotypic heterogeneity of GT remains poorly understood. Currently, based on the expression and functionality of residual subunits, GT is classified into 3 types: <5% residual αIIbβ3 signifies type I, 5%-20% residual of αIIbβ3 comprises type II and >20% of residual αIIbβ3 constitutes variant-type GT. Due to the clinical phenotypic heterogeneity of GT, a diagnosis of GT is often overlooked, as a normal platelet count on a routine blood smear does not exclude a diagnosis of GT. In addition to a complete medical history, a GT diagnosis requires a comprehensive laboratory workup, including platelet aggregation analysis, and a confirmation of integrin αIIbβ3 deficiency by flow cytometry or western blotting with monoclonal antibodies that recognize either αIIb or β3 subunits or the αIIbβ3 complex. The best diagnostic method for GT is through genetic testing of the ITGA2B and ITGB3 genes, which allows a definitive diagnosis.
To date, 256 variants in ITGA2B and 164 variants in ITGB3 have been identified (http://sinaicentral.mssm.edu/intranet/research/ glanzmann/search). However, most were individual case reports. [8] [9] [10] [11] [12] [13] [14] Large patient cohort studies were concentrated in countries with high intermarriage rates, such as Iraqi Jews, 15 
| Platelet aggregation analysis
Peripheral blood samples were obtained from 97 patients and plateletrich plasma was prepared. Platelet aggregations were performed in the presence of collagen 1.2 μg/mL, adenosine diphosphate (ADP) 2 μM and 1.5 mg/mL ristocetin as agonist. Platelet aggregometry was performed using a CHRONO-LOG MODEL 700 aggregometer.
| Flow cytometry
Expression of glycoproteins on the surface of washed platelets was performed by flow cytometry with a Cytomics TM FC500 flow cytometer using fluorescein isothiocyanate conjugated anti-CD41, anti-CD61 and anti-CD42 monoclonal antibodies (MoAbs). For PAC-1 binding, washed platelets were pre-incubated with 0.25 U/mL thrombin for 30 minutes in 37 C. About 25 μg/mL FITC-labeled PAC-1 was then added.
| Sequencing analysis and variants identification
Among 97 GT patients, peripheral blood samples of 45 patients were available for genetic analysis. After obtaining patient consent, genomic DNA was prepared from peripheral blood leukocytes isolated from whole blood of 45 GT patients. All exons from ITGA2B and ITGB3
genes were amplified by PCR using intronic primers. 3 | RESULTS
| Clinical features
We examined the clinical features of 97 GT patients from 93 families, including 53 females and 44 males (Table S1 , Supporting Information).
Patient ages ranged from 1 to 53 years. Most patients suffered from mucocutaneous petechia (77.3%), epistaxis (69.1%), gingival bleeding (36.1%), post-traumatic hemorrhage (19.6%) and gastrointestinal bleeding (12.4%). They also experienced rare GT manifestations, such as hematuria, intracranial hemorrhage and hemarthrosis (5.2%). About 90.6% of females had menorrhagia after menarche, 12.5% had a ruptured corpus luteum, and 6.25% suffered from infertility ( Table 1) .
The average bleeding score in female and male patients was 2.96 
| Comparison of clinical manifestations among different ethnic populations
Given these gender differences, we also compared the clinical mani- Table 2 ). All ethnic groups had no significant differences in the distribution of GT type. Type I and type II are the most common, and type III is the rarest.
| Molecular genetic analysis
Among the 45 GT patients with genomic DNA samples, sequencing results were compared with the sequence for ITGA2B (NCBI:
NG_008331.1) and ITGB3 (NCBI: NG_008332.2) using the BLAST software through PubMed. We detected 43 different variants (ITGA2B: n = 28, ITGB3: n = 15), which reveals the genetic diversity of GT in the Han population from China (Table S2 ). These variants Fifteen patients were homozygotes, 21 patients were compound heterozygotes, while 7 patients were identified only 1 heterozygous variant and 2 patients harbored no pathogenic variant on ITGA2B or ITGB3 ( Figure 2 ). These results stand in consensus with other reports that did not identify pathogenic variants in some patients (Table 2) . 16, 17, 23 Here, our 25 novel pathogenic variants included 14 missense (ITGA2B: n = 9, ITGB3: n = 5), 4 nonsense (ITGA2B: n = 2, ITGB3: n = 2), 3 splicing (ITGA2B), and 4 frameshift (ITGA2B: n = 1, ITGB3: n = 3). Among them, 11 were "pathogenic variant", and 14 were "likely pathogenic variants" (Table S2 ). We uncovered 9 amino acid substitutions in αIIb located in the β-propeller domain (c.812C>G in 7, 4, 7, and 2 unrelated families, respectively. We first reported p.
R584X in 2 type I GT siblings in 1993. 10 They were both heterozygous. Indeed, we found more patients harboring this mutation here.
This p.R584X mutation involves a CpG hotspot, which may alter its reproducibility. p.Q891X is another mutation previously identified in Chinese type I GT. 24 Functional studies show that impaired transport of the pro-αIIbβ3 complex from the endoplasmic reticulum to the Golgi underlies thrombasthenia. 24 p.C400Y was previously identified in the Chinese population. 25 Transient transfection in CHO cells showed that this mutation causes an 85% to 90% reduction in GPllb/ llla surface expression, even though these cells retain the ability to adhere to immobilized fibrinogen. These results suggest that these variants are pathogenic and reveal hotspot mutations in China, which may reflect a founder effect. Furthermore, p.Q778P has been reported in 7 Japanese patients [26] [27] [28] and 2 Korean patients, 29 suggesting that p.Q778P may be another hotspot pathogenic variant in the Asian population.
| Clinical phenotypic variation in a compound heterozygous patient
Twenty-one compound heterozygotes were identified in this study. 
| DISCUSSION
By comparing clinical differences between the Han population and other ethnic groups, we revealed key distinguishing characteristics.
First, consanguinity contributes to a much lower frequency in GT patients from the Han population than other ethnic populations, as most GT patients in the Han population were compound heterozygotes (46.7%). We found 7 patients (GT2, GT3, GT12, GT22, GT27, GT34, GT36) who has only 1 heterozygous variant in ITGA2B or ITGB3 gene. It is possible that the other allele may be deleted or the second pathogenic variant may be located in other gene, which we are not able to find due to the limitation of our current detection method. This heterozygous genetic pattern prevents elimination of these pathogenic variants, suggesting asymptomatic, heterozygous subjects compose a relatively high frequency in the Han population. This result underscores the necessity for gene screening.
These results can update the pathogenic variant database to improve early diagnosis of acatalepsia patients. In addition, it can facilitate prenatal diagnosis and carrier detection, which is important to control the disorder among family members. Second, the mortality rate in China is relatively high. We suggest the mortality rate is related to the low consanguinity rate, because doctors may ignore the possibility of a recessive genetic disorder in a nonconsanguineous family. Proper care and appropriate treatment in emergencies can largely reduce the mortality risk of GT. Therefore, it is vital to improve our understanding of this rare disease to improve the early diagnosis rate for disease management.
The reasons for the heterogeneity of bleeding symptoms in GT have been unclear. Evaluating the phenotype of patients with the same genotype will elucidate the relationship between genotype and phenotype in GT. GT4, GT17b, and GT18 were all Q891X homozygotes and type I GT, but the severity of the bleeding varied significantly. This suggests that genotype is not the only determinant of bleeding heterogeneity and further suggests that heterogeneity is a multifactorial symptom. However, genotype may regulate αIIbβ3 expression, because patients with the same genotype generally had the same GT type (Table 3 ). We also examined whether different domains correlate with bleeding heterogeneity, however, we did not find a significant correlation (data not shown). (Figure 4) . F857 breaks the disulfide bond to influence integrin stability or conformation, which affects ligand binding. R590 is a highly conservative and exposed residue ( Figure 4) . Q590 changed the polarity of amino acids in the site, such that the positively charged arginine was converted into an uncharged glutamine. This change could affect αIIbβ3 conformation.
So far, several pathogenic variants have been identified that underlie the loss-of-function variant forms. 32, 33 Proportionally, the highest concern is ITGB3, and lowest concern is ITGA2B. 32, 33 Moreover, most are located on the headpiece of the αIIbβ3 complex. 32, 33 Only a few defects on other parts have been identified, specifically β3 H626L, β3
S752P and αIIb V951M. This case implied an interesting structurefunction relationship between the different αIIbβ3 domains and highlighted the importance of αIIb for proper function αIIbβ3, especially other domains except β-propeller. We acknowledge this case was unique compared to the majority of GT cases. He did not have any abnormal bleeding before extradural hemorrhage, although he had bumps, small traumas or needle injections prior to that event. It is possible that other factors affect platelet aggregation besides ITGA2B
and ITGB3 genes.
| CONCLUSION
In summary, we investigated the clinical and genetic characteristics of 97 GT patients from 93 families in China. To our knowledge, this is the first large cohort study of GT patients from the Han population in China. Our results reveal critical insights into GT heterogeneity and show key differences between phenotypes and genotypes from other consanguineous populations in the world.
